Portable Monitoring Device for the Diagnosis of Sleep Apnea in Obese Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01455077|
Recruitment Status : Unknown
Verified October 2011 by Prof. Dr. Lia Azeredo-Bittencourt, Associacao Fundo de Incentivo a Psicofarmcologia.
Recruitment status was: Recruiting
First Posted : October 19, 2011
Last Update Posted : October 19, 2011
Introduction The portable monitoring system (PMS) recording of cardiopulmonary parameters (level III of ASDA) has been validated in subjects with high probability of Obstructive Sleep Apnea (OSA) without comorbidities.
However, there is not any study evaluating this system when OSA is associated with morbid obesity, so the validation of PMS will be very useful in order to properly work-up this highly risk population.
To evaluate the accuracy of level III type of PMS - Stardust™" (STD), on patients with level II and III of obesity and high clinical suspicion of OSA.
Methods:Participants with BMI > 35 kg/m2 and with suspicion of OSA will consecutively be selected from an Outpatients Sleep Clinic of UNIFESP. They will be randomized for the following order of recordings:
1) STD at home for 1 night 2) STD in the sleep lab simultaneous to PSG. AHI will be taken for subsequent analysis:a) AHI PSG b) AHI STD -lab and c) AHI STD- home.
|Condition or disease|
|Obstructive Sleep Apnea Syndrome Obesity|
|Study Type :||Observational|
|Estimated Enrollment :||40 participants|
|Observational Model:||Ecologic or Community|
|Official Title:||Validation of a Portable Monitoring System for the Diagnosis of Obstructive Sleep Apnea Syndrome in Patients With Level II and III Obesity|
|Study Start Date :||January 2011|
|Actual Primary Completion Date :||July 2011|
|Estimated Study Completion Date :||January 2012|
BMI > 35
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01455077
|Contact: Lia R Bittencourt, MD, PhD||55 11 firstname.lastname@example.org|
|Associacao Fundo de Incentivo a Psicofarmacologia||Recruiting|
|São Paulo, SP, Brazil|
|Contact: Lia R Bittencourt, MD, PhD 55 11 21490155 email@example.com|
|Contact: Erika C Treptow firstname.lastname@example.org|
|Sub-Investigator: Erika C Treptow|